J&J Medical Connect
Neuroscience
Neuroscience

Congress Materials – Alzheimer's Association International Conference (AAIC 2026)

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Consistent Cognitive And Functional Outcomes Across Prespecified Subgroups In The Autonomy Trial Evaluating Posdinemab In Early AD

Colell MGV, Veroff A, Bogert J, Coyle PC, Fedgchin M, Berghmans PJ, Henley D, Xu H, Saad ZS, Elwood F, Simen A,Wong J


This document will be available after July 12th 2026

Safety And Tolerability Of Posdinemab In Early Alzheimer's Disease: Results From The Phase 2 Autonomy Trial

Berghmans PJ, Fedgchin M, Watkins PB, Snoeys J, Tyler R, Meyer M, Bogert J, De Jonghe S, Jeong A, Li L, Henley D, Greenberg H, Marquez L, Xu H, Simen A, Wong J


This document will be available after July 12th 2026

Speech-Based Biomarkers for Assessing Cognitive Status in Preclinical Alzheimer’s Disease: Insights from the REtAIN Study

Kyani A, Parisi F, Kaliukhovich DA, Mallol-Ragolta A, Colell MGV, Demanuele C, Farrell K, Linz N, Tröger J, Herrmann J, Wittenberg G, Simen A, Elwood F, Thornton-Wells T, Steukers L


This document will be available after July 12th 2026

Speech-Based Biomarkers for Evaluating Tau PET Status in Preclinical Alzheimer’s Disease: Insights from the REtAIN Study

Parisi F, Kaliukhovich DA, Colell MGV, Demanuele C, Linz N, Tröger J, Herrmann J, Slania S, Saad ZS, Wittenberg G, Simen A, Elwood F, Thornton-Wells T, Steukers L, Kyani A


This document will be available after July 12th 2026

Tau PET Results From The Phase 2b Autonomy Trial Evaluating Posdinemab In Early Alzheimer’s Disease

Saad ZS, Slania S, Datta R, Zhang X, Li J, Abdollahi R, Huang X, Bogert J, Fedgchin M, Berghmans PJ, Kolb HC, Henley D, Van der Geyten S, Xu H, Wittenberg G, Simen A, Elwood F, Wong J


This document will be available after July 14th 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

Would you like to clear and leave your conversation? Message history will be lost.